We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.51B
1-Year Est. Return 164.17%
This Fund
S&P 500
This Quarter Est. Return
-8.83%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$3.57B
AUM Growth
-$614M
Cap. Flow
+$51.4M
Cap. Flow %
1.44%
Top 10 Hldgs %
48.82%
Holding
78
New
14
Increased
15
Reduced
33
Closed
9

Top Buys

Rank Stock Value
1
BEAM icon
Beam Therapeutics
BEAM
+$73M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$72.6M
3
ONEM
1Life Healthcare
ONEM
+$68.5M
4
MRK icon
Merck
MRK
+$64.9M
5
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$53.9M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$116M
2
FTSV
Forty Seven, Inc. Common Stock
FTSV
+$109M
3
BSX icon
Boston Scientific
BSX
+$73.8M
4
CNC icon
Centene
CNC
+$44.2M
5
HCA icon
HCA Healthcare
HCA
+$42.2M

Sector Composition

Rank Sector Weight
1 Healthcare 97.84%
2 Industrials 0.87%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GTHX
76
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
– –
-613,734
Closed -$16.2M
FTSV
77
DELISTED
Forty Seven, Inc. Common Stock
FTSV
– –
-2,770,842
Closed -$109M
BOLD
78
DELISTED
Audentes Therapeutics, Inc
BOLD
– –
-639,095
Closed -$38.2M
1 2 3
4

Similar funds

KP
Keel Point Huntsville, Alabama $1.51B AUM 20.06% 1-Year Est. Return
FMI
F/M Investments Washington, District of Columbia $1.51B AUM 25.86% 1-Year Est. Return
FCM
Fairholme Capital Management South Miami, Florida $1.51B AUM 28.27% 1-Year Est. Return
SCM
SG Capital Management Chicago, Illinois $1.51B AUM 49.98% 1-Year Est. Return
PP
PDS Planning Dublin, Ohio $1.52B AUM 18.08% 1-Year Est. Return
AM
Ares Management Los Angeles, California $1.52B AUM 12.97% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Redmile Group's Q1 2020 Portfolio in Review

As of Q1 2020, Redmile Group held 78 positions worth $3.57B, down 15% from $4.18B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Redmile Group's Q1 2020 filing shows 14 new, 15 increased, 33 reduced and 9 closed positions. Its largest new stake was Beam Therapeutics: 3,359,258 shares worth $60.5M. The largest sale was Bristol-Myers Squibb, an estimated $116M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 98% a quarter earlier, followed by Industrials and Technology.

  • Redmile Group's largest Q1 2020 buy was Beam Therapeutics: 3,359,258 shares worth $60.5M.
  • Redmile Group added most to Momenta Pharmaceuticals, Inc. in Q1 2020, an estimated $53.9M increase.
  • Redmile Group's biggest Q1 2020 reduction was Centene, cutting an estimated $44.2M.
  • Redmile Group fully exited Bristol-Myers Squibb in Q1 2020, selling an estimated $116M.
  • Redmile Group's ten largest holdings make up 49% of its $3.57B portfolio in Q1 2020.
  • Redmile Group opened 14 new positions and closed 9 in Q1 2020.
  • Redmile Group's portfolio value fell 15% quarter-over-quarter to $3.57B.

Based on Redmile Group's 13F filing for Q1 2020, filed 15 May 2020.